Acrivon Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Acrivon Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($18.23M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($21.01M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($21.01M) | Nov 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($19.68M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($19.68M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($19.68M) | Nov 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($22.44M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($18.80M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.80M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($16.49M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.49M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($16.49M) | Nov 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($14.47M) | Nov 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($13.91M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.91M) | Aug 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($12.76M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($12.76M) | Nov 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.76M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($9.20M) | Nov 9, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($5.82M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($19.69M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($22.65M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($21.66M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($25.14M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($21.44M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($17.67M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.14M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.52M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.39M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($9.58M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($5.93M) | Aug 11, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.21M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($2.67M) | Dec 15, 2022 |